The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: Impact for diagnostics and pharmacogenetics

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 4, 2003, Pages 452-461

  Frueh, Felix W ^a,b   Noyer Weidner, Mario ^a  

^a Transgenomic Ltd   (Germany)

^b Stepoutside Consulting   (United States)

Author keywords

Denaturing high performance liquid chromatography (DHPLC); Genotyping; Mutation detection; Mutation screening; Pharmacogenetics; Single nucleotide polymorphism (SNP)

Indexed keywords

DIHYDROPYRIDINE; DNA; FLUOROURACIL; IMMUNOSUPPRESSIVE AGENT; MITOCHONDRIAL DNA; RNA; THIOPURINE METHYLTRANSFERASE;

ACCURACY; ACUTE LEUKEMIA; BREAST CANCER; COLORECTAL CANCER; DNA DETERMINATION; EARLY DIAGNOSIS; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE COST; HETERODUPLEX ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; MOLECULAR GENETICS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; SEQUENCE ANALYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS);

EID: 0038059078     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.068     Document Type: Review

References (82)

1. McPherson JD, Marra M, Hillier L, Waterston RH, Chinwalla A, Wallis J, et al. A physical map of the human genome. Nature 2001; 409:934-41.
2. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291:1304-51.
3. Cronin MT, Pho M, Dutta D, Frueh F, Schwarcz L, Brennan T. Utilization of new technologies in drug trials and discovery. Drug Metab Dispos 2001; 29(4 Pt 2):586-90.
4. Frueh FW, Hayashibara KC, Brown PO, Whitlock JP Jr. Use of cDNA microarrays to analyze dioxin-induced changes in human liver gene expression. Toxicol Lett 2001; 122:189-203.
5. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409:928-33.
6. Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2001; 2: 930-42.
7. Delwart EL, Sheppard HW, Walker BD, Goudsmit J, Mullins JI. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol 1994; 68:6672-83.
8. Delwart EL, Gordon CJ. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods 1997; 12:348-54.
9. Underhill PA, Jin L, Zemans R, Oefner PJ, Cavalli-Sforza LL. A pre-Columbian Y chromosome-specific transition and its implications for human evolutionary history. Proc Natl Acad Sci USA 1996; 93:196-200.
10. Bonn G, Huber C, Oefner R Nucleic acid separation on alkylated nonporous polymer beads. US patent 5,585,236. 1996.
11. Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: a review. Hum Mutat 2001; 17:439-74.
12. Hayward AL, Oefner PJ, Sabatini S, Kainer DB, Hinojos CA, Doris PA. Modeling and analysis of competitive RT-PCR. Nucleic Acids Res 1998; 26:2511-8.
13. Doris PA, Oefner PJ, Chilton BS, Hayward-Lester A. Quantitative analysis of gene expression by ion-pair high-performance liquid chromatography. J Chromatogr A 1998; 806:47-60.
14. Devaney JM, Marino MA. Purification methods for preparing polymerase chain reaction products for capillary electrophoresis analysis. Methods Mol Biol 2001; 162:43-9.
15. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2 + channel gene CACNL1A4. Cell 1996; 87:543-52.
16. Underhill PA, Jin L, Lin AA, Mehdi SQ, Jenkins T, Vollrath D, et al. Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. Genome Res 1997; 7:996-1005.
17. Gross E, Kiechle M, Arnold N. Mutation analysis of p53 in ovarian tumors by DHPLC. J Biochem Biophys Methods 2001; 47:73-81.
18. Keller G, Hartmann A, Mueller J, Hofler H. Denaturing high pressure liquid chromatography (DHPLC) for the analysis of somatic p53 mutations. Lab Invest 2001; 81:1735-7.
19. Gross E, Arnold N, Pfeifer K, Bandick K, Kiechle M. Identification of specific BRCA1 and BRCA2 variants by DHPLC. Hum Mutat 2000; 16:345-53.
20. Wagner T, Stoppa-Lyonnet D, Fleischmann E, Muhr D, Pages S, Sandberg T, et al. Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 1999; 62:369-76.
21. Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet 1999; 105:72-8.
22. Wu G, Wu W, Hegde M, Fawkner M, Chong B, Love D, et al. Detection of sequence variations in the adenomatous polyposis coli (APC) gene using denaturing high-performance liquid chromatography. Genet Test 2001; 5:281-90.
23. Toomajian C, Kreitman M. Sequence variation and haplotype structure at the human HFE locus. Genetics 2002; 161:1609-23.
24. Le Gac G, Mura C, Ferec C. Complete scanning of the hereditary hemochromatosis gene (HFE) by use of denaturing HPLC. Clin Chem 2001; 47:1633-40.
25. Bennett RR, Dunnen J, O'Brien KF, Darras BT, Kunkel LM. Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing. BMC Genet 2001; 2:17.
26. Ravnik-Glavac M, Atkinson A, Glavac D, Dean M. DHPLC screening of cystic fibrosis gene mutations. Hum Mutat 2002; 19:374-83.
27. Le Marechal C, Audrezet MP, Quere I, Raguenes O, Langonne S, Ferec C. Complete and rapid scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-performance liquid chromatography (D-HPLC): major implications for genetic counselling. Hum Genet 2001; 108:290-8.
28. Buyse IM, Fang P, Hoon KT, Amir RE, Zoghbi HY, Roa BB. Diagnostic testing for Rett syndrome by DHPLC and direct sequencing analysis of the MECP2 gene: identification of several novel mutations and polymorphisms. Am J Hum Genet 2000; 67:1428-36.
29. Nicolao P, Carella M, Giometto B, Tavolato B, Cattin R, Giovannucci-Uzielli ML, et al. DHPLC analysis of the MECP2 gene in Italian Rett patients. Hum Mutat 2001; 18:132-40.
30. Hoffbuhr K, Devaney JM, LaFleur B, Sirianni N, Scacheri C, Giron J, et al. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 2001; 56:1486-95.
31. Frusconi S, Passerini I, Girolami F, Masieri M, Linari S, Longo G, et al. Identification of seven novel mutations of F8C by DHPLC. Hum Mutat 2002; 20:231-2.
32. Weirich G, Cabras AD, Serra S, Coni PP, Nurchi AM, Faa G, et al. Rapid identification of Wilson's disease carriers by denaturing high-performance liquid chromatography. Prev Med 2002; 35:278-84.
33. Halliday DJ, Hutchinson S, Lonie L, Hurst JA, Firth H, Handford PA, et al. Twelve novel FBN1 mutations in Marfan syndrome and Marfan related phenotypes test the feasibility of FBN1 mutation testing in clinical practice. J Med Genet 2002; 39:589-93.
34. Choy YS, Dabora SL, Hall F, Ramesh V, Niida Y, Franz D, et al. Superiority of denaturing high performance liquid chromatography over single-stranded conformation and conformation-sensitive gel electrophoresis for mutation detection in TSC2. Ann Hum Genet 1999; 63(Pt 5):383-91.
35. Bunn CF, Lintott CJ, Scott RS, George PM. Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Hum Mutat 2002; 19:311.
36. Eng C, Brody LC, Wagner TM, Devilee P, Vijg J, Szabo C, et al. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 2001; 38:824-33.
37. Roden DM, George AL Jr. The genetic basis of variability in drug responses. Nat Rev Drug Discov 2002; 1:37-44.
38. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalized medicine [review]. AAPS Pharm-Sci 2000; 2:E4.
39. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-91.
40. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356:1667-71.
41. Legrand-Andreoletti M, Stucker I, Marez D, Galais P, Cosme J, Sabbagh N, et al. Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians. Pharmacogenetics 1998; 8:7-14.
42. Schaeffeler E, Lang T, Zanger UM, Eichelbaum M, Schwab M. High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem 2001; 47: 548-55.
43. Hall AG, Hamilton P, Minto L, Coulthard SA. The use of denaturing high-pressure liquid chromatography for the detection of mutations in thiopurine methyltransferase. J Biochem Biophys Methods 2001; 47:65-71.
44. Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 2002; 306:63-73.
45. Roden DM. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 2001; 50:224-31.
46. Silber MB, Pharmacogenomics, biomarkers, and the promise of personalized medicine. Kalow W, Meyer UA, Tyndale RF, editors. Pharmacogenomics. New York and Basel: Marcel Dekker, Inc., 2001:11-31.
47. Napolitano C, Priori SG. Genetics of ventricular tachycardia. Curr Opin Cardiol 2002; 17:222-8.
48. Vatta M, Dumaine R, Antzelevitch C, Brugada R, Li H, Bowles NE, et al. Novel mutations in domain I of SCN5A cause Brugada syndrome. Mol Genet Metab 2002; 75: 317-24.
49. Wang Z, Li H, Moss AJ, Robinson J, Zareba W, Knilans T, et al. Compound heterozygous mutations in KvLQT1 cause Jervell and Lange-Nielsen syndrome. Mol Genet Metab 2002; 75:308-16.
50. Jongbloed R, Marcelis C, Velter C, Doevendans P, Geraedts J, Smeets H. DHPLC analysis of potassium ion channel genes in congenital long QT syndrome. Hum Mutat 2002; 20:382-91.
51. Warren WJ, Vella G. Principles and methods for the analysis and purification of synthetic deoxyribonucleotides by high-performance liquid chromatography. Mol Biotechnol 1995; 4:179-99.
52. Devaney JM, Pettit EL, Kaler SG, Vallone PM, Butler JM, Marino MA. Genotyping of two mutations in the HFE gene using single-base extension and high-performance liquid chromatography. Anal Chem 2001; 73:620-4.
53. Giordano M, Mellai M, Hoogendoorn B, Momigliano-Richiardi P. Determination of SNP allele frequencies in pooled DNAs by primer extension genotyping and denaturing high-performance liquid chromatography. J Biochem Biophys Methods 2001; 47:101-10.
54. Hoogendoorn B, Norton N, Kirov G, Williams N, Hamshere ML, Spurlock G, et al. Cheap, accurate and rapid allele frequency estimation of single nucleotide polymorphisms by primer extension and DHPLC in DNA pools. Hum Genet 2000; 107:488-93.
55. Austin J, Hoogendoorn B, Buckland P, Speight G, Cardno A, Bowen T, et al. Comparative sequencing of the proneurotensin gene and association studies in schizophrenia. Mol Psychiatry 2000; 5:208-12.
56. Hoogendoorn B, Owen MJ, Oefner PJ, Williams N, Austin J, O'Donovan MC. Genotyping single nucleotide polymorphisms by primer extension and high performance liquid chromatography. Hum Genet 1999; 104:89-93.
57. Vallone PM, Devaney JM, Marino MA, Butler JM. A strategy for examining complex mixtures of deoxyoligonucleotides using ion-pair-reverse-phase high-performance liquid chromatography, matrix-assisted laser desorption ionization time-of-flight mass spectrometry, and informatics. Anal Biochem 2002; 304:257-65.
58. Takeda S, Nakao A. Genetic detection and clinical applications in patients with hepatocellular carcinoma. Nippon Geka Gakkai Zasshi 2002; 103:472-5.
59. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002; 315:157-68.
60. Srinivas PR, Kramer BS, Srivastava S. Trends in biomarker research for cancer detection. Lancet Oncol 2001; 2:698-704.
61. Wolford JK, Blunt D, Ballecer C, Prochazka M. High-throughput SNP detection by using DNA pooling and denaturing high performance liquid chromatography (DHPLC). Hum Genet 2000; 107:483-7.
62. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, et al. Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002; 99:9433-8.
63. Gjerde DT, Hanna CP, Hornby DP. DNA chromatography. Weinheim, Germany: Wiley-VCH Verlag GmbH, 2002.
64. Marino MA, Rudolph JG, McAndrew P, Legendre B, Breen JJ. Detection of low-level mutations using fluorescent heteroduplex DHPLC analysis. In: 93rd Annual Meeting of the American Association for Cancer Research, 2001. San Francisco, CA: AACR.
65. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283:1482-8.
66. Chinnery PF, Howell N, Andrews RM, Turnbull DM. Clinical mitochondrial genetics. J Med Genet 1999; 36:425-36.
67. van Den Bosch BJ, de Coo RF, Scholte HR, Nijland JG, van Den Bogaard R, de Visser M, et al. Mutation analysis of the entire mitochondrial genome using denaturing high performance liquid chromatography. Nucleic Acids Res 2000; 28:E89.
68. Liu MR, Pan KF, Li ZF, Wang Y, Deng DJ, Zhang L, et al. Rapid screening mitochondrial DNA mutation by using denaturing high-performance liquid chromatography. World J Gastroenterol 2002; 8:426-30.
69. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69:915-26.
70. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247-57.
71. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293:1068-70.
72. Muyrers-Chen I, Paro R. Epigenetics: unforeseen regulators in cancer. Biochim Biophys Acta 2001; 1552:15-26.
73. Jones PA. DNA methylation and cancer. Oncogene 2002; 21:5358-60.
74. Novik KL, Nimmrich I, Genc B, Maier S, Piepenbrock C, Olek A, et al: Epigenomics: genome-wide study of methylation phenomena. Curr Issues Mol Biol 2002; 4:111-28.
75. Wong IH. Methylation profiling of human cancers in blood: molecular monitoring and prognostication [review]. Int J Oncol 2001; 19:1319-24.
76. Jubb AM, Bell SM, Quirke P. Methylation and colorectal cancer. J Pathol 2001; 195:111-34.
77. Oakeley EJ. DNA methylation analysis: a review of current methodologies. Pharmacol Ther 1999; 84:389-400.
78. Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques 2002; 33:632, 634, 636-49.
79. El-Maarri O, Herbiniaux U, Walter J, Oldenburg J. A rapid, quantitative, non-radioactive bisulfite-SNuPE-IP RP HPLC assay for methylation analysis at specific CpG sites. Nucleic Acids Res 2002; 30:e25.
80. Deng D, Deng G, Smith MF, Zhou J, Xin H, Powell SM, et al. Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography. Nucleic Acids Res 2002; 30:E13.
81. Baumer A. Analysis of the methylation status of imprinted genes based on methylation-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography. Methods 2002; 27:139-43.
82. Baumer A, Wiedemann U, Hergersberg M, Schinzel A. A novel MSP/DHPLC method for the investigation of the methylation status of imprinted genes enables the molecular detection of low cell mosaicisms. Hum Mutat 2001; 17:423-30.